

# Yasuhito Tanaka

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3580048/yasuhito-tanaka-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

450  
papers

16,023  
citations

60  
h-index

106  
g-index

473  
ext. papers

18,096  
ext. citations

6.6  
avg, IF

6.14  
L-index

#	Paper	IF	Citations
450	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	6
449	Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019.. <i>Scientific Reports</i> , <b>2022</b> , 12, 1517	4.9	2
448	Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application.. <i>Scientific Reports</i> , <b>2022</b> , 12, 2133	4.9	0
447	Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263844	3.7	0
446	Management of HBV reactivation in patients with resolved HBV infection based on a highly-sensitive HB core-related antigen assay.. <i>Hepatology Research</i> , <b>2022</b> ,	5.1	2
445	Anti-nuclear antibody and a granuloma could be biomarkers for iCIIs-related hepatitis by anti-PD-1 treatment.. <i>Scientific Reports</i> , <b>2022</b> , 12, 3669	4.9	0
444	The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C <b>2022</b> , 1, 508-515		
443	Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation.. <i>Journal of Gastroenterology</i> , <b>2022</b> , 1	6.9	1
442	Complex structural variations in non-human primate hepatitis B virus. <i>Virology Journal</i> , <b>2021</b> , 18, 200	6.1	
441	All-atom molecular dynamics study of hepatitis B virus containing pregenome RNA in solution. <i>Journal of Chemical Physics</i> , <b>2021</b> , 155, 145101	3.9	1
440	Clinical impact of gastrointestinal endoscopy on the early detection of pharyngeal squamous cell carcinoma: A retrospective cohort study. <i>World Journal of Gastrointestinal Endoscopy</i> , <b>2021</b> , 13, 491-501	2.2	0
439	Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. <i>Microorganisms</i> , <b>2021</b> , 9,	4.9	6
438	Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
437	Blocking neddylation elicits antiviral effect against hepatitis B virus replication. <i>Molecular Biology Reports</i> , <b>2021</b> , 1	2.8	0
436	Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients. <i>International Journal of Clinical Oncology</i> , <b>2021</b> , 26, 922-932	4.2	2
435	Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. <i>Hepatology Research</i> , <b>2021</b> , 51, 528-537	5.1	2
434	Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. <i>Cancer Science</i> , <b>2021</b> , 112, 1943-1954	6.9	3

433	Co-continuous structural effect of size-controlled macro-porous glass membrane on extracellular vesicle collection for the analysis of miRNA. <i>Scientific Reports</i> , <b>2021</b> , 11, 8672	4.9	1
432	Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009228	7.6	1
431	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
430	Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in nonviral hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2021</b> ,	5.1	3
429	N-glycan structures of Wisteria floribunda agglutinin-positive Mac2 binding protein in the serum of patients with liver fibrosis. <i>Glycobiology</i> , <b>2021</b> , 31, 1268-1278	5.8	0
428	Breakthrough HBV infection in a vaccinated child due to vaccine escape mutant. <i>Acta Hepatologica Japonica</i> , <b>2021</b> , 62, 403-412	0.3	
427	Novel strategies for the early diagnosis of hepatitis B virus reactivation. <i>Hepatology Research</i> , <b>2021</b> , 51, 1033-1043	5.1	6
426	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 46-60.e8	6.9	15
425	Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course. <i>Hepatology Research</i> , <b>2021</b> , 51, 239-244	5.1	0
424	Identification of a novel long-acting 4Pmodified nucleoside reverse transcriptase inhibitor against HBV. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1075-1086	13.4	5
423	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , <b>2021</b> , 15, 71-81	8.8	4
422	Application of fluorescent-based technology detecting protein-protein interactions to monitor the binding of hepatitis B virus X protein to DNA-damage-binding protein 1. <i>Biophysics and Physicobiology</i> , <b>2021</b> , 18, 67-77	1.4	
421	Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	4
420	Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 224, 1410-1421	7	1
419	Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 302-310	13.4	18
418	A case of child-to-father transmission of hepatitis B virus in Japan: a rare infection route. <i>Clinical Journal of Gastroenterology</i> , <b>2021</b> , 14, 1706-1710	1.1	
417	A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257166	3.7	1
416	Reply to: "Understanding HBcrAg components improves the interpretation of clinical HBcrAg assay results". <i>Journal of Hepatology</i> , <b>2021</b> , 75, 998-999	13.4	3

415	Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0261878	3.7	1
414	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , <b>2020</b> , 14, 1023-1033	8.8	10
413	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	17
412	Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes. <i>Scientific Reports</i> , <b>2020</b> , 10, 21718	4.9	4
411	Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , <b>2020</b> , 60, 51-54	1.9	7
410	Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 285-293	13.4	11
409	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. <i>Hepatology International</i> , <b>2020</b> , 14, 225-238	8.8	15
408	Tolloid-Like 1 Negatively Regulates Hepatic Differentiation of Human Induced Pluripotent Stem Cells Through Transforming Growth Factor Beta Signaling. <i>Hepatology Communications</i> , <b>2020</b> , 4, 255-267 <sup>6</sup>		1
407	JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 640-652	6.9	3
406	7-Deaza-7-fluoro modification confers on 4Pcyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. <i>Antiviral Research</i> , <b>2020</b> , 176, 104744	10.8	6
405	MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion. <i>Cancer Science</i> , <b>2020</b> , 111, 869-880	6.9	15
404	Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. <i>Liver Cancer</i> , <b>2020</b> , 9, 207-220	9.1	7
403	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1420-1425	4	1
402	Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	15
401	Fluorescence-based biochemical analysis of human hepatitis B virus reverse transcriptase activity. <i>Analytical Biochemistry</i> , <b>2020</b> , 597, 113642	3.1	2
400	Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis. <i>Hepatology Research</i> , <b>2020</b> , 50, 840-852	5.1	21
399	Free energy profile of permeation of Entecavir through Hepatitis B virus capsid studied by molecular dynamics calculation. <i>Pure and Applied Chemistry</i> , <b>2020</b> , 92, 1585-1594	2.1	2
398	Reduction of T-Box 15 gene expression in tumor tissue is a prognostic biomarker for patients with hepatocellular carcinoma. <i>Oncotarget</i> , <b>2020</b> , 11, 4803-4812	3.3	2

397	MicroRNA and liver cancer. <b>2020</b> , 3, 385-400		0
396	Novel biomarkers for the management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 261-279	6.9	28
395	Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 855-861	4	18
394	Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. <i>Hepatology</i> , <b>2020</b> , 71, 1910-1922	11.2	34
393	Hepatitis B virus-related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccination. <i>Hepatology Research</i> , <b>2020</b> , 50, 182-189	5.1	6
392	Successful treatment of adult-onset type II citrullinemia with a low-carbohydrate diet and L-arginine after DNA analysis produced a definitive diagnosis. <i>Clinical Journal of Gastroenterology</i> , <b>2020</b> , 13, 823-833	1.1	3
391	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, 271-280	0.7	45
390	Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. <i>Carcinogenesis</i> , <b>2020</b> , 41, 1145-1157	4.6	15
389	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2840-2848	11.6	14
388	Inhibitory Effect of a Human MicroRNA, miR-6133-5p, on the Fibrotic Activity of Hepatic Stellate Cells in Culture. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
387	Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA. <i>Virus Research</i> , <b>2020</b> , 290, 198191	6.4	10
386	Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 977-989	6.9	6
385	Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. <i>Liver International</i> , <b>2020</b> , 40, 2961-2971	7.9	12
384	Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus. <i>Hepatology Research</i> , <b>2020</b> , 50, 1128-1140	5.1	3
383	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 776-787	18.8	51
382	East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1540-1550	6.1	6
381	Cross-Protection of Hepatitis B Vaccination among Different Genotypes. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	7
380	Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. <i>Infectious Diseases and Therapy</i> , <b>2020</b> , 9, 851-866	6.2	6

379	Analysis of Hepatitis B Virus Genotype D in Greenland Suggests the Presence of a Novel Quasi-Subgenotype. <i>Frontiers in Microbiology</i> , <b>2020</b> , 11, 602296	5.7	1
378	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. <i>Hepatology International</i> , <b>2019</b> , 13, 587-598	8.8	22
377	The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection. <i>Scientific Reports</i> , <b>2019</b> , 9, 13393	4.9	1
376	CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	11
375	Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz185	1	13
374	Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems. <i>Antiviral Research</i> , <b>2019</b> , 169, 104537	10.8	6
373	Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?. <i>Clinical Journal of Gastroenterology</i> , <b>2019</b> , 12, 598-602	1.1	2
372	Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	7
371	The Role of Hepatitis B Core-Related Antigen. <i>Genes</i> , <b>2019</b> , 10,	4.2	20
370	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 473-485	13.4	47
369	Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. <i>Hepatology Communications</i> , <b>2019</b> , 3, 493-503	6	16
368	The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1230-1241	6.1	24
367	The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1060-1070	6.1	13
366	Clinical Evaluation of a Newly Developed Chemiluminescent Enzyme Immunoassay for Hepatitis C Virus Core Antigen in Japan. <i>Japanese Journal of Infectious Diseases</i> , <b>2019</b> , 72, 285-291	2.7	1
365	Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 8487-8492	11.5	97
364	An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People. <i>Hepatology</i> , <b>2019</b> , 69, 19-33	11.2	13
363	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 364-369	4	20
362	MEG3-derived miR-493-5p overcomes the oncogenic feature of IGF2-miR-483 loss of imprinting in hepatic cancer cells. <i>Cell Death and Disease</i> , <b>2019</b> , 10, 553	9.8	26

361	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2 infected patients in a real-world setting in Japan. <i>Journal of Viral Hepatitis</i> , <b>2019</b> , 26, 1266-1275	3.4	13
360	Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. <i>Experimental and Therapeutic Medicine</i> , <b>2019</b> , 18, 596-604	2.1	1
359	Factors associated with longitudinal changes in serum concentrations of Mac-2 binding protein: A prospective 3-year observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2019</b> , 29, 1337-1344 <sup>3</sup>	4.5	3
358	Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224184	3.7	5
357	Hepatitis C Virus Infection <b>2019</b> , 323-330		
356	Clinical usefulness of a newly developed high-sensitive hepatitis B surface antigen (HBsAg) assay for monitoring hepatitis B reactivation. <i>Acta Hepatologica Japonica</i> , <b>2019</b> , 60, 237-247	0.3	4
355	Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. <i>Journal of Gastroenterology</i> , <b>2019</b> , 54, 87-95	6.9	53
354	Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 107-115	6.1	46
353	Influence of renal dysfunction on dose reduction and virologic efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection. <i>Hepatology Research</i> , <b>2019</b> , 49, 512-520	5.1	2
352	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <i>Blood</i> , <b>2019</b> , 133, 137-146	2.2	59
351	TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy. <i>Journal of Gastroenterology</i> , <b>2019</b> , 54, 339-346	6.9	14
350	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. <i>Hepatology Research</i> , <b>2019</b> , 49, 125-135	5.1	11
349	Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , <b>2019</b> , 54, 427-436	6.9	16
348	Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. <i>Hepatology International</i> , <b>2018</b> , 12, 133-142	8.8	14
347	High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 883-889	6.9	24
346	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. <i>Hepatology Research</i> , <b>2018</b> , 48, 549-555	5.1	16
345	Gut Dysbiosis Associated With Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 869-877	11.6	85
344	Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients. <i>Hepatology Research</i> , <b>2018</b> , 48, 134-143	5.1	10

343	Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 247-257	6.9	12
342	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 119-128	6.9	40
341	Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 438-448	6.9	15
340	Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus. <i>Hepatology Research</i> , <b>2018</b> , 48, E203-E212	5.1	15
339	Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. <i>Hepatology International</i> , <b>2018</b> , 12, 356-367	8.8	31
338	Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer. <i>Hepatology Research</i> , <b>2018</b> , 48, 1081-1091	5.1	4
337	Suppression of hepatitis B surface antigen production by combination therapy with nucleotide analogues and interferon in children with genotype C hepatitis B virus infection. <i>Hepatology Research</i> , <b>2018</b> , 48, 1172-1177	5.1	5
336	Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment. <i>Cancer Letters</i> , <b>2018</b> , 434, 91-100	9.9	14
335	Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. <i>Journal of Gastroenterology</i> , <b>2018</b> , 53, 1276-1284	6.9	20
334	Intrahepatic Cross-Presentation and Hepatocellular Antigen Presentation Play Distinct Roles in the Induction of Hepatitis B Virus-Specific CD8 T Cell Responses. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	16
333	Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. <i>Internal Medicine</i> , <b>2018</b> , 57, 951-956	1.1	5
332	IV. Hepatitis B treatment: beyond disease control to functional cure. <i>The Journal of the Japanese Society of Internal Medicine</i> , <b>2018</b> , 107, 32-37	0	
331	Antiviral therapy for hepatitis B virus during second pregnancies. <i>Journal of Obstetrics and Gynaecology Research</i> , <b>2018</b> , 44, 566-569	1.9	6
330	Host genetic variations associated with disease progression in chronic hepatitis C virus infection. <i>Hepatology Research</i> , <b>2018</b> , 48, 127-133	5.1	14
329	Screening of microRNAs for a repressor of hepatitis B virus replication. <i>Oncotarget</i> , <b>2018</b> , 9, 29857-29863	6.3	6
328	Serial changes of NS5A P32deletion mutant in HCV genotype 1b patients after Daclatasvir/Asunaprevir failure. <i>Acta Hepatologica Japonica</i> , <b>2018</b> , 59, 230-233	0.3	2
327	Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, ofy268	1	13
326	Clinical Evaluation of Hepatocarcinogenesis and Outcome Using a Novel Glycobiomarker Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) in Chronic Hepatitis C with Advanced Fibrosis. <i>Japanese Journal of Infectious Diseases</i> , <b>2018</b> , 71, 177-183	2.7	5



325	How are HBV-specific CD8+ T-cell responses induced?. <i>Future Virology</i> , <b>2018</b> , 13, 825-827	2.4	1
324	Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 1128-1137	6.1	20
323	Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	7
322	De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. <i>Cell Chemical Biology</i> , <b>2018</b> , 25, 906-915.e5	8.2	35
321	Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2018</b> , 48, 872-881	5.1	10
320	Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells. <i>Molecular Therapy</i> , <b>2018</b> , 26, 1840-1854	11.7	36
319	Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 94-103	6.9	35
318	Genome-Wide Association Study Identifies Risk Variants for Lichen Planus in Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 937-944.e5	6.9	17
317	Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. <i>Hepatology Research</i> , <b>2017</b> , 47, 1165-1173	5.1	12
316	Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection. <i>Gastroenterology</i> , <b>2017</b> , 152, 1383-1394	13.3	76
315	Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 1922-1927	11.5	33
314	Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1029-1035	3.3	17
313	Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 685-692	13.4	74
312	Interferon- $\alpha$ response is impaired by hepatitis B virus infection in <i>Tupaia belangeri</i> . <i>Virus Research</i> , <b>2017</b> , 237, 47-57	6.4	13
311	Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection. <i>Scientific Reports</i> , <b>2017</b> , 7, 45698	4.9	34
310	Effects of vaccine-acquired polyclonal anti-HBs antibodies on the prevention of HBV infection of non-vaccine genotypes. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 1051-1063	6.9	8
309	Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. <i>Hepatology Research</i> , <b>2017</b> , 47, 1308-1316	5.1	33
308	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 1122-1129	6.9	28

307	Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 1241-1247	19.7	7
306	Novel monitoring of hepatitis B reactivation based on ultra-high sensitive hepatitis B surface antigen assay. <i>Liver International</i> , <b>2017</b> , 37, 1138-1147	7.9	26
305	Serum IFN- $\beta$ Levels Correlate with Serum Hepatitis C Virus RNA Levels in Symptomatic Patients with Acute Hepatitis C. <i>Digestive Diseases</i> , <b>2017</b> , 35, 531-540	3.2	1
304	Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181603	3.7	1
303	Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 477-486	3.4	6
302	Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma. <i>Case Reports in Gastroenterology</i> , <b>2017</b> , 11, 701-710	1	6
301	Functional association of cellular microtubules with viral capsid assembly supports efficient hepatitis B virus replication. <i>Scientific Reports</i> , <b>2017</b> , 7, 10620	4.9	29
300	Identification of the novel 3'UTR sequences of human IL-21 mRNA as potential targets of miRNAs. <i>Scientific Reports</i> , <b>2017</b> , 7, 7780	4.9	13
299	A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins. <i>Hepatology</i> , <b>2017</b> , 65, 1104-1116	11.2	46
298	Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. <i>Clinical Journal of Gastroenterology</i> , <b>2017</b> , 10, 41-46	1.1	3
297	Molecular epidemiology of co-infection with hepatitis B virus and human immunodeficiency virus (HIV) among adult patients in Harare, Zimbabwe. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 257-266	19.7	9
296	Hepatitis B virus X protein impairs Interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. <i>Journal of Medical Virology</i> , <b>2017</b> , 89, 267-275	19.7	23
295	Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. <i>Journal of Gastroenterology</i> , <b>2017</b> , 52, 376-384	6.9	15
294	Reply. <i>Gastroenterology</i> , <b>2017</b> , 153, 1449-1450	13.3	1
293	A human PSMB11 variant affects thymoproteasome processing and CD8+ T cell production. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	6
292	Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0170667	3.7	2
291	Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation. <i>Antiviral Research</i> , <b>2016</b> , 133, 156-64	10.8	18
290	Smoking is a risk factor for development of adult T-cell leukemia/lymphoma in Japanese human T-cell leukemia virus type-1 carriers. <i>Cancer Causes and Control</i> , <b>2016</b> , 27, 1059-66	2.8	5

289 Host Genetics and Responses to Antiviral Therapy in Chronic Hepatitis C **2016**, 225-241

288 Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha-fetoprotein assessment. *Cancer Medicine*, **2016**, 5, 3102-3110 4.8 15

287 Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2. *Digestive Diseases*, **2016**, 34, 627-631 3.2 4

286 The value of serum Wisteria floribunda agglutinin-positive human Mac-2-binding protein as a predictive marker for hepatitis C virus-related complications after systemic chemotherapy. *International Journal of Hematology*, **2016**, 104, 384-91 2.3 2

285 Global, cancer-specific microRNA cluster hypomethylation was functionally associated with the development of non-B non-C hepatocellular carcinoma. *Molecular Cancer*, **2016**, 15, 31 42.1 10

284 Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. *Journal of Gastroenterology*, **2016**, 51, 741-7 6.9 63

283 Hepatitis B and C Virus Infection and Risk of Pancreatic Cancer: A Population-Based Cohort Study (JPHC Study Cohort II). *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 555-7 4 25

282 Property of hepatitis B virus replication in *Tupaia belangeri* hepatocytes. *Biochemical and Biophysical Research Communications*, **2016**, 469, 229-35 3.4 18

281 A Novel Drug-Resistant HIV-1 Circulating Recombinant Form CRF76\_01B Identified by Near Full-Length Genome Analysis. *AIDS Research and Human Retroviruses*, **2016**, 32, 284-9 1.6 5

280 Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. *Journal of Hepatology*, **2016**, 64, 547-55 13.4 45

279 Genome-Wide Association Study Identifies ZNF354C Variants Associated with Depression from Interferon-Based Therapy for Chronic Hepatitis C. *PLoS ONE*, **2016**, 11, e0164418 3.7 7

278 Hepatitis B virus and its sexually transmitted infection - an update. *Microbial Cell*, **2016**, 3, 420-437 3.9 55

277 Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013. *Journal of Pediatric Gastroenterology and Nutrition*, **2016**, 63, 88-93 2.8 11

276 Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. *Liver International*, **2016**, 36, 642-50 7.9 5

275 Host genetic variants influencing the clinical course of hepatitis C virus infection. *Journal of Medical Virology*, **2016**, 88, 185-95 19.7 26

274 Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C. *Hepatology*, **2016**, 64, 732-45 11.2 67

273 A novel glyco-biomarker, Wisteria floribunda agglutinin macrophage colony-stimulating factor receptor, for predicting carcinogenesis of liver cirrhosis. *International Journal of Cancer*, **2016**, 138, 1462-71 7.5 11

272 Host genetic variants influencing the clinical course of hepatitis B virus infection. *Journal of Medical Virology*, **2016**, 88, 371-9 19.7 32

271	Virological characteristics of hepatitis B genotype G/A2 recombination virus in Japan. <i>Hepatology Research</i> , <b>2016</b> , 46, 775-83	5.1	2
270	Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. <i>Liver International</i> , <b>2016</b> , 36, 827-36	7.9	42
269	JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. <i>Hepatology Research</i> , <b>2016</b> , 46, 129-65	5.1	48
268	Serum levels of Mac-2 binding protein increase with cardiovascular risk and reflect silent atherosclerosis. <i>Atherosclerosis</i> , <b>2016</b> , 251, 192-196	3.1	21
267	Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2016</b> , 31, 180-9	4	25
266	Factors associated with the effect of interferon- $\beta$ sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B. <i>Hepatology Research</i> , <b>2015</b> , 45, 1195-202	5.1	18
265	Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy. <i>International Journal of Hematology</i> , <b>2015</b> , 101, 398-404	2.3	28
264	Hepatitis B and C virus infection and risk of lymphoid malignancies: A population-based cohort study (JPHC Study). <i>Cancer Epidemiology</i> , <b>2015</b> , 39, 562-6	2.8	26
263	Natural history of chronic hepatitis B virus infection in childhood and efficacy of interferon therapy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 892-9	2.4	4
262	Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 719-29	11.6	106
261	Characterization of novel entecavir resistance mutations. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 546-53	13.4	41
260	Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 829-37	13.4	40
259	Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells. <i>Journal of Virology</i> , <b>2015</b> , 89, 7016-27	6.6	8
258	A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide. <i>Journal of Virology</i> , <b>2015</b> , 89, 11945-53	6.6	57
257	Genome-wide association study identifies a PSMD3 variant associated with neutropenia in interferon-based therapy for chronic hepatitis C. <i>Human Genetics</i> , <b>2015</b> , 134, 279-89	6.3	8
256	The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. <i>Immunity</i> , <b>2015</b> , 42, 123-32	32.3	279
255	Postexposure prophylactic effect of hepatitis B virus (HBV)-active antiretroviral therapy against HBV infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 1292-8	5.9	4
254	Immunobiology of hepatitis B virus infection. <i>Hepatology Research</i> , <b>2015</b> , 45, 179-89	5.1	36

253	Hepatitis B surface gene variants isolated from blood donors with overt and occult HBV infection in north eastern Egypt. <i>Virology Journal</i> , <b>2015</b> , 12, 153	6.1	11
252	Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. <i>Hepatology Research</i> , <b>2015</b> , 45, 1363-7	5.1	33
251	4Pmodified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. <i>Hepatology</i> , <b>2015</b> , 62, 1024-36	11.2	36
250	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137351	3.7	19
249	Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to hepatitis B virus infection through modulation of sodium taurocholate cotransporting polypeptide (NTCP) expression. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 5673-84	5.4	43
248	microRNAs and Hepatitis B. <i>Advances in Experimental Medicine and Biology</i> , <b>2015</b> , 888, 389-99	3.6	7
247	Plasma isoflavones and risk of primary liver cancer in Japanese women and men with hepatitis virus infection: a nested case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 532-7	4	16
246	Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118000	3.7	8
245	Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118062	3.7	19
244	Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C. <i>Hepatology Research</i> , <b>2014</b> , 44, 1208-1216	5.1	8
243	Role of IL28B for chronic hepatitis C treatment toward personalized medicine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 241-9	4	38
242	Hepatitis virus infection affects DNA methylation in mice with humanized livers. <i>Gastroenterology</i> , <b>2014</b> , 146, 562-72	13.3	80
241	Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. <i>Liver International</i> , <b>2014</b> , 34, 890-5	7.9	15
240	Strategy for preventing hepatitis B reactivation in patients with resolved hepatitis B virus infection after rituximab-containing chemotherapy. <i>Hepatology</i> , <b>2014</b> , 60, 765-6	11.2	4
239	ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type. <i>Journal of Viral Hepatitis</i> , <b>2014</b> , 21, 466-74	3.4	8
238	Mechanisms for interferon-Induced depression and neural stem cell dysfunction. <i>Stem Cell Reports</i> , <b>2014</b> , 3, 73-84	8	46
237	Application of a glycoproteomics-based biomarker development method: alteration in glycan structure on colony stimulating factor 1 receptor as a possible glyco-biomarker candidate for evaluation of liver cirrhosis. <i>Journal of Proteome Research</i> , <b>2014</b> , 13, 1428-37	5.6	25
236	Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). <i>Hepatology</i> , <b>2014</b> , 59, 1726-37	11.2	185

235	Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. <i>Hepatology Research</i> , <b>2014</b> , 44, E38-E44	5.1	6
234	Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. <i>Journal of Infectious Diseases</i> , <b>2014</b> , 210, 701-7	7	9
233	Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. <i>Hepatology</i> , <b>2014</b> , 59, 89-97	11.2	65
232	New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. <i>PLoS ONE</i> , <b>2014</b> , 9, e86449	3.7	28
231	Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population. <i>PLoS ONE</i> , <b>2014</b> , 9, e86007	3.7	23
230	Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti-HCV antibody in an HCV hyperendemic area in Japan. <i>Journal of Medical Virology</i> , <b>2014</b> , 86, 1877-85	19.7	4
229	Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. <i>Hepatology Research</i> , <b>2014</b> , 44, 354-7	5.1	24
228	IFetoprotein is a surrogate marker for predicting treatment failure in telaprevir-based triple combination therapy for genotype 1b chronic hepatitis C Japanese patients with the IL28B minor genotype. <i>Journal of Medical Virology</i> , <b>2014</b> , 86, 461-72	19.7	6
227	Pretreatment prediction of the outcome of response-guided peginterferon- and ribavirin therapy for chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 1996-2005	4	2
226	Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2014</b> , 29, 201-7	4	11
225	Novel point mutations and mutational complexes in the enhancer II, core promoter and precore regions of hepatitis B virus genotype D1 associated with hepatocellular carcinoma in Saudi Arabia. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 2864-71	7.5	25
224	Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C. <i>Hepatology International</i> , <b>2013</b> , 7, 153-61	8.8	4
223	Molecular epidemiology and genetic history of hepatitis C virus subtype 3a infection in Thailand. <i>Intervirology</i> , <b>2013</b> , 56, 284-94	2.5	26
222	Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. <i>Journal of Medical Virology</i> , <b>2013</b> , 85, 1900-6	19.7	24
221	Factors of response to pegylated interferon/ribavirin combination therapy and mechanism of viral clearance. <i>Digestive Diseases</i> , <b>2013</b> , 31, 421-5	3.2	1
220	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotypes 2a and 2b and high viral load. <i>Digestive Diseases</i> , <b>2013</b> , 31, 426-33	3.2	2
219	Hepatitis C virus kinetics by administration of pegylated interferon- in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene. <i>Gut</i> , <b>2013</b> , 62, 1340-6	19.2	21
218	Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C. <i>Journal of Medical Virology</i> , <b>2013</b> , 85, 250-60	19.7	14

217	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C. <i>Journal of Medical Virology</i> , <b>2013</b> , 85, 449-58	19.7	9
216	2PFluoro-6Pmethylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2013</b> , 23, 503-6	2.9	13
215	Glycoproteomic discovery of serological biomarker candidates for HCV/HBV infection-associated liver fibrosis and hepatocellular carcinoma. <i>Journal of Proteome Research</i> , <b>2013</b> , 12, 2630-40	5.6	45
214	Tracing the spread of hepatitis C virus in Turkey: a phylogenetic analysis. <i>Intervirology</i> , <b>2013</b> , 56, 201-5	2.5	4
213	In vitro replication competence of a hepatitis B genotype D/A recombinant virus: dissimilar biological behaviour regarding its parental genotypes. <i>Journal of General Virology</i> , <b>2013</b> , 94, 2724-2728	4.9	1
212	Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 3484-91	9.7	51
211	Evolutionary analysis of hepatitis C virus gene sequences from 1953. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , <b>2013</b> , 368, 20130168	5.8	14
210	Interleukin-1 and tumor necrosis factor- $\alpha$ trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 31715-27	5.4	111
209	Hepatitis C virus genotype 2 may not be detected by the Cobas AmpliPrep/Cobas TaqMan HCV Test, Version 1.0. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 4275-6	9.7	5
208	Plasma levels of adiponectin and primary liver cancer risk in middle-aged Japanese adults with hepatitis virus infection: a nested case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2013</b> , 22, 2250-7	4	12
207	Outcome of double-filtration plasmapheresis plus interferon treatment in nonresponders to pegylated interferon plus ribavirin combination therapy. <i>Digestive Diseases</i> , <b>2013</b> , 31, 434-9	3.2	3
206	Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. <i>Hepatology Research</i> , <b>2013</b> , 43, 113-21	5.1	15
205	Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4480	2.2	5
204	Hepatic failure in pregnancy successfully treated by online hemodiafiltration: Chronic hepatitis B virus infection without viral genome mutation. <i>Hepatology Research</i> , <b>2013</b> , 43, 1356-1360	5.1	2
203	Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. <i>Microbiology and Immunology</i> , <b>2013</b> , 57, 122-9	2.7	9
202	A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. <i>Scientific Reports</i> , <b>2013</b> , 3, 1065	4.9	236
201	Targeted induction of interferon- $\beta$ in humanized chimeric mouse liver abrogates hepatotropic virus infection. <i>PLoS ONE</i> , <b>2013</b> , 8, e59611	3.7	32
200	Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. <i>PLoS ONE</i> , <b>2013</b> , 8, e66920	3.7	31

199	Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 6214-20	5.6	15
198	The Cobas AmpliPrep/Cobas TaqMan real-time polymerase chain reaction assay produced false-negative results in two patients with hepatitis C virus genotype 2. <i>Acta Hepatologica Japonica</i> , <b>2013</b> , 54, 507-508	0.3	
197	Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. <i>Hepatology Research</i> , <b>2012</b> , 42, 139-49	5.1	47
196	Response-guided therapy for patients with chronic hepatitis who have high viral loads of hepatitis C virus genotype 2. <i>Hepatology Research</i> , <b>2012</b> , 42, 549-57	5.1	8
195	Replication and infectivity of a novel genotype 1b hepatitis C virus clone. <i>Microbiology and Immunology</i> , <b>2012</b> , 56, 308-17	2.7	19
194	Development of new IL28B genotyping method using Invader Plus assay. <i>Microbiology and Immunology</i> , <b>2012</b> , 56, 318-23	2.7	5
193	Multiple intra-familial transmission patterns of hepatitis B virus genotype D in north-eastern Egypt. <i>Journal of Medical Virology</i> , <b>2012</b> , 84, 587-95	19.7	25
192	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , <b>2012</b> , 7, 98-105	8.8	24
191	Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy. <i>Journal of Gastroenterology</i> , <b>2012</b> , 47, 1323-35	6.9	5
190	Development of a prediction model for 10-year risk of hepatocellular carcinoma in middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort II. <i>Preventive Medicine</i> , <b>2012</b> , 55, 137-43	4.3	34
189	Comparison of Lect-Hepa and FibroScan for assessment of liver fibrosis in hepatitis B virus infected patients with different ALT levels. <i>Clinica Chimica Acta</i> , <b>2012</b> , 413, 1796-9	6.2	9
188	Lect-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. <i>Hepatology</i> , <b>2012</b> , 56, 1448-56	11.2	34
187	No association for Chinese HBV-related hepatocellular carcinoma susceptibility SNP in other East Asian populations. <i>BMC Medical Genetics</i> , <b>2012</b> , 13, 47	2.1	34
186	Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. <i>Gastroenterology</i> , <b>2012</b> , 142, 1468-75	13.3	134
185	Novel evidence of HBV recombination in family cluster infections in western China. <i>PLoS ONE</i> , <b>2012</b> , 7, e38241	3.7	13
184	Soluble MICA and a MICA variation as possible prognostic biomarkers for HBV-induced hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2012</b> , 7, e44743	3.7	65
183	Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load. <i>Journal of Gastroenterology</i> , <b>2012</b> , 47, 1143-51	6.9	14
182	Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone. <i>Journal of Virology</i> , <b>2012</b> , 86, 10805-20	6.6	37



181	Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. <i>Journal of Virology</i> , <b>2012</b> , 86, 2212-20	6.6	46
180	Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1. <i>Journal of Virology</i> , <b>2012</b> , 86, 2143-52	6.6	12
179	A noncanonical mu-1A-binding motif in the N terminus of HIV-1 Nef determines its ability to downregulate major histocompatibility complex class I in T lymphocytes. <i>Journal of Virology</i> , <b>2012</b> , 86, 3944-51	6.6	7
178	Prospective Nationwide Observational Study of Hepatitis B Virus (HBV) DNA Monitoring and Preemptive Antiviral Therapy for HBV Reactivation in Patients with B-Cell Non-Hodgkin Lymphoma Following Rituximab Containing Chemotherapy: Results of Interim Analysis.. <i>Blood</i> , <b>2012</b> , 120, 2641-2641	2.2	9
177	Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. <i>PLoS ONE</i> , <b>2012</b> , 7, e39175	3.7	117
176	Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment. <i>Digestion</i> , <b>2011</b> , 84 Suppl 1, 50-5	3.6	2
175	Lect-Hepa: A triplex lectin-antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine. <i>Clinica Chimica Acta</i> , <b>2011</b> , 412, 1767-72	6.2	26
174	Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study). <i>Cancer Letters</i> , <b>2011</b> , 300, 173-9	9.9	24
173	Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 19-25	13.4	13
172	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 439-48	13.4	104
171	Cross-species transmission of gibbon and orangutan hepatitis B virus to uPA/SCID mice with human hepatocytes. <i>Virus Research</i> , <b>2011</b> , 158, 209-15	6.4	3
170	The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. <i>Journal of Clinical Microbiology</i> , <b>2011</b> , 49, 1852-60	9.7	60
169	Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009. <i>Hepatology Research</i> , <b>2011</b> , 41, 1-21	5.1	22
168	Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial. <i>Hepatology Research</i> , <b>2011</b> , 41, 505-11	5.1	4
167	Clarification of interspousal hepatitis C virus infection in acute hepatitis C patients by molecular evolutionary analyses: Consideration on sexual and non-sexual transmission between spouses. <i>Hepatology Research</i> , <b>2011</b> , 41, 838-45	5.1	2
166	Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin. <i>Hepatology Research</i> , <b>2011</b> , 41, 1216-22	5.1	6
165	Favorable factors for re-treatment with pegylated interferon $\alpha$ plus ribavirin in patients with high viral loads of genotype 1 hepatitis C virus. <i>Hepatology Research</i> , <b>2011</b> , 41, 1169-77	5.1	4
164	Genetic variation of the IL-28B promoter affecting gene expression. <i>PLoS ONE</i> , <b>2011</b> , 6, e26620	3.7	39

163	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 685-94	1.6	34
162	Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C. <i>Journal of Pharmacological Sciences</i> , <b>2011</b> , 115, 263-9	3.7	10
161	Antiviral activity of novel 2Pfluoro-6Pmethylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2011</b> , 21, 6328-31	2.9	10
160	A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan. <i>Journal of Gastroenterology</i> , <b>2011</b> , 46, 117-24	6.9	20
159	Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. <i>Journal of Gastroenterology</i> , <b>2011</b> , 46, 9-16	6.9	71
158	Molecular characterization of hepatitis B virus isolates from Zimbabwean blood donors. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 235-44	19.7	13
157	Host sphingolipid biosynthesis is a promising therapeutic target for the inhibition of hepatitis B virus replication. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 587-93	19.7	27
156	Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 412-8	19.7	42
155	Investigating an outbreak of acute viral hepatitis caused by hepatitis E virus variants in Karachi, South Pakistan. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 622-9	19.7	20
154	Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 871-8	19.7	43
153	Hepatitis C pharmacogenetics: state of the art in 2010. <i>Hepatology</i> , <b>2011</b> , 53, 336-45	11.2	120
152	Transmissibility of hepatitis B virus (HBV) infection through blood transfusion from blood donors with occult HBV infection. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 52, 624-32	11.6	68
151	Multilectin assay for detecting fibrosis-specific glyco-alteration by means of lectin microarray. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 48-56	5.5	61
150	Genome-wide association study identified ITPA/DDRKG1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 3507-16	5.6	75
149	Double-Filtration Plasmapheresis plus Interferon- $\alpha$ For HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy. <i>Digestion</i> , <b>2011</b> , 84 Suppl 1, 10-6	3.6	3
148	The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1007-8	0.7	14
147	Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 202, 202-13	7	35
146	Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 882-9	5.9	29

145	Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 1663-71	7	27
144	RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells. <i>PLoS Pathogens</i> , <b>2010</b> , 6, e1000885	7.6	45
143	Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. <i>Gastroenterology</i> , <b>2010</b> , 139, 499-509	13.3	352
142	Biological properties of purified recombinant HCV particles with an epitope-tagged envelope. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 395, 565-71	3.4	9
141	Molecular epidemiology of hepatitis C virus genotypes in west Mexico. <i>Virus Research</i> , <b>2010</b> , 151, 19-25	6.4	17
140	Geographical and genetic diversity of the human hepatitis B virus. <i>Hepatology Research</i> , <b>2010</b> , 40, 14-30	5.1	150
139	lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. <i>Hepatology Research</i> , <b>2010</b> , 40, 449-60	5.1	38
138	High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. <i>Hepatology Research</i> , <b>2010</b> , 40, 956-62	5.1	14
137	ITPA gene variant protects against anemia induced by pegylated interferon and ribavirin therapy for Japanese patients with chronic hepatitis C. <i>Hepatology Research</i> , <b>2010</b> , 40, 1063-71	5.1	58
136	Molecular epidemiological study of hepatitis B virus among migrant workers from Cambodia, Laos, and Myanmar to Thailand. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1341-9	19.7	33
135	JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B. <i>Acta Hepatologica Japonica</i> , <b>2010</b> , 51, 243-260	0.3	
134	Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. <i>International Journal of Hematology</i> , <b>2010</b> , 91, 844-9	2.3	18
133	Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 257-62	19.7	50
132	Occult hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1527-36	19.7	49
131	Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: evaluation on HCV genotypes 1-4. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1878-88	19.7	19
130	Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection: Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. <i>Acta Hepatologica Japonica</i> , <b>2009</b> , 50, 38-42	0.3	62
129	The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 1940-6; quiz 1947	0.7	61
128	Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 385-9	9.7	22

127	Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. <i>Journal of Clinical Microbiology</i> , <b>2009</b> , 47, 1476-83	9.7	97
126	A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. <i>Journal of Virology</i> , <b>2009</b> , 83, 10538-47	6.6	298
125	Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2009</b> , 18, 1746-53	4	88
124	Isoflavone consumption and subsequent risk of hepatocellular carcinoma in a population-based prospective cohort of Japanese men and women. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 1644-9	7.5	37
123	Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 1189-97	19.7	42
122	Genetic variability of hepatitis C virus in South Egypt and its possible clinical implication. <i>Journal of Medical Virology</i> , <b>2009</b> , 81, 1015-23	19.7	38
121	Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II). <i>Cancer Causes and Control</i> , <b>2009</b> , 20, 741-50	2.8	46
120	Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. <i>International Journal of Hematology</i> , <b>2009</b> , 90, 13-23	2.3	134
119	Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. <i>Nature Genetics</i> , <b>2009</b> , 41, 1105-9	36.3	1926
118	Strategy for glycoproteomics: identification of glyco-alteration using multiple glycan profiling tools. <i>Journal of Proteome Research</i> , <b>2009</b> , 8, 1358-67	5.6	63
117	Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 80-8	13.4	411
116	Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. <i>Gastroenterology</i> , <b>2009</b> , 136, 652-62.e3	13.3	48
115	HBV genotypes in India: do they influence disease severity?. <i>Hepatology Research</i> , <b>2009</b> , 39, 157-63	5.1	18
114	Impact of determination of hepatitis B virus subgenotype and pre-core/core-promoter mutation for the prediction of acute exacerbation of asymptomatic carriers. <i>Hepatology Research</i> , <b>2009</b> , 39, 341-5	5.1	4
113	Case-control study for the identification of virological factors associated with fulminant hepatitis B. <i>Hepatology Research</i> , <b>2009</b> , 39, 648-56	5.1	32
112	Serum aminotransferase level and the risk of hepatocellular carcinoma: a population-based cohort study in Japan. <i>European Journal of Cancer Prevention</i> , <b>2009</b> , 18, 26-32	2	32
111	Universal hepatitis B vaccination: pros and cons. <i>Acta Hepatologica Japonica</i> , <b>2009</b> , 50, 598-604	0.3	2
110	Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2008</b> , 23, 474-81	4	28

109	Characteristics of hepatitis B virus genotype G coinfecting with genotype H in chimeric mice carrying human hepatocytes. <i>Virology</i> , <b>2008</b> , 376, 408-15	3.6	32
108	What can be revealed by extending the sensitivity of HBsAg detection to below the present limit?. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 17-24	13.4	13
107	Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia. <i>Virus Research</i> , <b>2008</b> , 132, 174-80	6.4	23
106	Development and public release of a comprehensive hepatitis virus database. <i>Hepatology Research</i> , <b>2008</b> , 38, 234-43	5.1	47
105	Detection of hepatitis C virus natural recombinant RF1_2k/1b strain among intravenous drug users in Uzbekistan. <i>Hepatology Research</i> , <b>2008</b> , 38, 457-64	5.1	44
104	Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis. <i>Hepatology Research</i> , <b>2008</b> , 38, 683-8	5.1	41
103	Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 1448-56	7	43
102	When should "I" consider a new hepatitis B virus genotype?. <i>Journal of Virology</i> , <b>2008</b> , 82, 8241-2	6.6	59
101	Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 217-24	19.7	25
100	Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. <i>Journal of Medical Virology</i> , <b>2008</b> , 80, 268-76	19.7	34
99	Transition and problems of hepatitis B virus genotypes among patients with acute and chronic infection in Japan. <i>Acta Hepatologica Japonica</i> , <b>2008</b> , 49, 549-552	0.3	1
98	Early dynamics of hepatitis B virus in chimeric mice carrying human hepatocytes monoinfected or coinfecting with genotype G. <i>Hepatology</i> , <b>2007</b> , 45, 929-37	11.2	35
97	Molecular epidemiological study of hepatitis B virus infection in two different ethnic populations from the Solomon Islands. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 229-35	19.7	18
96	Molecular evidence of father-to-child transmission of hepatitis B virus. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 922-6	19.7	29
95	Variations in the core promoter/pre-core region in HBV genotype C in Japanese and Northern Vietnamese patients. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1293-304	19.7	21
94	Virological features of hepatitis B virus-associated nephropathy in Japan. <i>Journal of Medical Virology</i> , <b>2007</b> , 79, 1305-11	19.7	16
93	A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation. <i>Virology</i> , <b>2007</b> , 361, 27-33	3.6	7
92	Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. <i>Virology</i> , <b>2007</b> , 365, 285-91	3.6	16

91	A weak association between occult HBV infection and non-B non-C hepatocellular carcinoma in Japan. <i>Journal of Gastroenterology</i> , <b>2007</b> , 42, 298-305	6.9	29
90	Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion. <i>Journal of Gastroenterology</i> , <b>2007</b> , 42, 837-44	6.9	14
89	Evaluation of anti-hepatitis E virus (HEV) immunoglobulin A in a serological screening for HEV infection. <i>Journal of Gastroenterology</i> , <b>2007</b> , 42, 911-7	6.9	13
88	Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 44, 541-8	11.6	65
87	Increasing genetic diversity of hepatitis C virus in haemophiliacs with human immunodeficiency virus coinfection. <i>Journal of General Virology</i> , <b>2007</b> , 88, 2513-2519	4.9	9
86	Genetic diversity of hepatitis B virus as an important factor associated with differences in clinical outcomes. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 1-4	7	32
85	Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 1487-92	7	80
84	Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 1491-6	9.7	69
83	Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 3942-7	9.7	124
82	Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2. <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 3191-7	9.7	51
81	Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. <i>Journal of Clinical Virology</i> , <b>2007</b> , 39, 87-93	14.5	62
80	Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. <i>Hepatology Research</i> , <b>2007</b> , 37, 179-85	5.1	3
79	Impaired cytotoxic T lymphocyte inductivity by dendritic cells derived from patients with hepatitis C virus-positive hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2007</b> , 37, 276-85	5.1	2
78	Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. <i>Hepatology Research</i> , <b>2007</b> , 37, 974-83	5.1	168
77	Japanese case of hepatitis B virus genotypes C/D hybrid. <i>Hepatology Research</i> , <b>2007</b> , 37, 1095-9	5.1	4
76	Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. <i>Hepatology</i> , <b>2006</b> , 44, 326-34	11.2	196
75	Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. <i>Hepatology</i> , <b>2006</b> , 44, 915-24	11.2	231
74	Tracing the history of hepatitis B virus genotype D in western Japan. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 44-52	19.7	28

73	Molecular epidemiology of hepatitis B virus in the United Republic of Tanzania. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 1035-42	19.7	14
72	Phylogenetic relatedness and genetic diversity of hepatitis B virus isolates in Eastern India. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 1164-74	19.7	85
71	High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. <i>Journal of Medical Virology</i> , <b>2006</b> , 78, 1688-95	19.7	42
70	T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, 1-7	11.6	70
69	Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds. <i>Intervirology</i> , <b>2006</b> , 49, 28-36	2.5	25
68	Molecular tracing of Japan-indigenous hepatitis E viruses. <i>Journal of General Virology</i> , <b>2006</b> , 87, 949-954	4.9	40
67	Molecular evolution of hepatitis B virus over 25 years. <i>Journal of Virology</i> , <b>2006</b> , 80, 10307-14	6.6	115
66	Prevalence of low positive anti-HCV antibodies in blood donors: <i>Schistosoma mansoni</i> co-infection and possible role of autoantibodies. <i>Microbiology and Immunology</i> , <b>2006</b> , 50, 447-52	2.7	20
65	Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. <i>Journal of General Virology</i> , <b>2006</b> , 87, 1873-1882	4.9	91
64	Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. <i>Gastroenterology</i> , <b>2006</b> , 130, 703-14	13.3	96
63	Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 646-53	13.4	116
62	Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. <i>Liver International</i> , <b>2006</b> , 26, 90-6	7.9	37
61	A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. <i>Hepatology Research</i> , <b>2006</b> , 35, 127-34	5.1	13
60	Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. <i>Hepatology Research</i> , <b>2006</b> , 36, 107-14	5.1	54
59	A case of acute hepatitis C in which transmission of HCV strain from a patient with chronic hepatitis C was demonstrated. <i>Acta Hepatologica Japonica</i> , <b>2006</b> , 47, 105-112	0.3	2
58	Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. <i>Intervirology</i> , <b>2005</b> , 48, 239-45	2.5	27
57	Tracing the evolution of hepatitis C virus in the United States, Japan, and Egypt by using the molecular clock. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, S82-5	6.9	15
56	Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 47-53	13.4	47

55	Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. <i>Liver International</i> , <b>2005</b> , 25, 247-53	7.9	27
54	Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. <i>Hepatology Research</i> , <b>2005</b> , 33, 216-24	5.1	51
53	A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. <i>Journal of General Virology</i> , <b>2005</b> , 86, 2047-2056	4.9	140
52	Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. <i>Journal of Clinical Microbiology</i> , <b>2005</b> , 43, 5679-84	9.7	86
51	Novel type of hepatitis B virus mutation: replacement mutation involving a hepatocyte nuclear factor 1 binding site tandem repeat in chronic hepatitis B virus genotype E. <i>Journal of Virology</i> , <b>2005</b> , 79, 14404-10	6.6	26
50	New combination test for hepatitis C virus genotype and viral load determination using Amplicor GT HCV MONITOR test v2.0. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 469-75	5.6	9
49	Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 6295-304	5.6	26
48	Distribution of HBV genotypes among HBV carriers in Benin: phylogenetic analysis and virological characteristics of HBV genotype E. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 6410-5	5.6	25
47	1. Round-table discussion on usefulness and future perspectives of the genotype research. <i>Acta Hepatologica Japonica</i> , <b>2005</b> , 46, 454-473	0.3	
46	Genotype of hepatitis virus. 3. Hepatitis C virus.. <i>Acta Hepatologica Japonica</i> , <b>2005</b> , 46, 480-485	0.3	
45	Novel hepatitis B virus genotype a subtyping assay that distinguishes subtype Aa from Ae and its application in epidemiological studies. <i>Journal of Virology</i> , <b>2004</b> , 78, 7575-81	6.6	18
44	Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. <i>Journal of General Virology</i> , <b>2004</b> , 85, 811-820	4.9	124
43	Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 1222-8	11.6	68
42	Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 38, 490-5	11.6	20
41	Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. <i>Journal of Clinical Microbiology</i> , <b>2004</b> , 42, 5036-40	9.7	31
40	Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. <i>Carcinogenesis</i> , <b>2004</b> , 25, 1593-8	4.6	85
39	Lack of association between occult hepatitis B virus DNA viral load and aminotransferase levels in patients with hepatitis C virus-related chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2004</b> , 19, 1343-7	4	11
38	Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE gene mutation in Japanese patients with nonalcoholic steatohepatitis. <i>Journal of Gastroenterology</i> , <b>2004</b> , 39, 654-60	6.9	25



37	Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection. <i>Journal of Gastroenterology</i> , <b>2004</b> , 39, 769-75	6.9	6
36	Molecular evolutionary analysis predicts the incidence of hepatocellular carcinoma in the United States and Japan. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2004</b> , 54 Suppl 1, S83-6	3.5	7
35	Exponential spread of hepatitis C virus genotype 4a in Egypt. <i>Journal of Molecular Evolution</i> , <b>2004</b> , 58, 191-5	3.1	68
34	A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. <i>Hepatology</i> , <b>2004</b> , 40, 747-55	11.2	127
33	Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study. <i>Journal of Medical Virology</i> , <b>2004</b> , 72, 551-7	19.7	53
32	PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. <i>Journal of Medical Virology</i> , <b>2004</b> , 73, 123-30	19.7	1
31	Reliability of hepatitis C virus core antigen assay for detection of viremia in HCV genotypes 1, 2, 3, and 4 infected blood donors: a collaborative study between Japan, Egypt, and Uzbekistan. <i>Journal of Medical Virology</i> , <b>2004</b> , 73, 216-22	19.7	31
30	Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. <i>Journal of Medical Virology</i> , <b>2004</b> , 73, 516-21	19.7	58
29	A randomized controlled trial of consensus interferon with or without lactoferrin for chronic hepatitis C patients with genotype 1b and high viral load. <i>Hepatology Research</i> , <b>2004</b> , 29, 9-12	5.1	15
28	Hepatitis B virus genotype G is an extremely rare genotype in Japan. <i>Hepatology Research</i> , <b>2004</b> , 30, 199-203	5.1	11
27	Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 119-25	13.4	60
26	Gianotti-Crosti syndrome caused by acute hepatitis B virus genotype D infection. <i>Internal Medicine</i> , <b>2004</b> , 43, 696-9	1.1	22
25	Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. <i>Intervirology</i> , <b>2003</b> , 46, 373-6	2.5	24
24	Transforming growth factor-beta-1 genetic polymorphism in Japanese patients with chronic hepatitis C virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2003</b> , 18, 1139-43	4	24
23	Hepatitis C virus molecular epidemiology in Uzbekistan. <i>Journal of Medical Virology</i> , <b>2003</b> , 69, 367-75	19.7	35
22	Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. <i>Journal of Medical Virology</i> , <b>2003</b> , 70, 529-36	19.7	82
21	High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. <i>Hepatology Research</i> , <b>2003</b> , 26, 261-267	5.1	22
20	Development of real-time detection direct test for hepatitis B virus and comparison with two commercial tests using the WHO international standard. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2003</b> , 18, 1264-71	4	15

19	Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2003</b> , 18, 1364-72	4	1
18	Human immunodeficiency virus in Uzbekistan: epidemiological and genetic analyses. <i>AIDS Research and Human Retroviruses</i> , <b>2003</b> , 19, 731-8	1.6	32
17	Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 1822-5	7	48
16	Prevalence of SEN viruses among injection drug users in the San Francisco Bay area. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 13-8	7	6
15	A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 15584-9	11.5	280
14	Observation of positive selection within hypervariable regions of a newly identified DNA virus (SEN virus)(1). <i>FEBS Letters</i> , <b>2002</b> , 510, 171-4	3.8	31
13	SEN virus infection and its relationship to transfusion-associated hepatitis. <i>Hepatology</i> , <b>2001</b> , 33, 1303-11	11.2	107
12	Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 359-67	7	138
11	Lack of integrated TT virus (TTV) genomes in cellular DNA in infected human hematopoietic cells. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 38, 411-7	1.9	9
10	Development of a TT virus DNA quantification system using real-time detection PCR. <i>Journal of Clinical Microbiology</i> , <b>2000</b> , 38, 94-8	9.7	32
9	Prevalence of TT virus and GBV-C infections among patients with liver diseases and the general population in Shanghai, China. <i>Virus Genes</i> , <b>1999</b> , 19, 51-8	2.3	6
8	Slow evolutionary rate of GB virus C/hepatitis G virus. <i>Journal of Molecular Evolution</i> , <b>1999</b> , 48, 383-9	3.1	20
7	TT virus infection among blood donors and patients with non-B, non-C liver diseases in Korea. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 389-93	13.4	25
6	High prevalence of TT virus infection in Japanese patients with liver diseases and in blood donors. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 221-7	13.4	43
5	Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. <i>FEBS Letters</i> , <b>1999</b> , 450, 66-71	3.8	190
4	African origin of GB virus C/hepatitis G virus. <i>FEBS Letters</i> , <b>1998</b> , 423, 143-8	3.8	26
3	New genotypes of TT virus (TTV) and a genotyping assay based on restriction fragment length polymorphism. <i>FEBS Letters</i> , <b>1998</b> , 437, 201-6	3.8	73
2	Analysis of conserved ambisense sequences within GB virus C. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 178, 1185-8	7	3

1 Analysis of Hepatitis B virus genotype D in Greenland suggests presence of a novel subgenotype

1